What separates the life sciences CEOs who build enduring companies from those who don't? In life sciences, the answer is rarely pedigree, network, or technical knowledge alone. It is the ability to speak two languages simultaneously, the language of science and the language of capital, and to be trusted in both rooms. Dual Fluency is the practitioner's guide to mastering that rare combination. Drawing on more than thirty years spanning M&A, licensing, partnering, and capital raises across numerous therapeutic disciplines, David H. Crean, PhD, MBA offers an unfiltered view of how transformative companies get built and sold and why so many promising ones quietly fall apart. This is not a textbook. It is not a retrospective written from the comfort of retirement. It is the operating thesis of a working professional who has sat on both sides of the table inside large pharma, alongside venture and private equity capital providers, and at the advisory helm of investment banking for some of the sector's most complex transactions. For founders, CEOs, business development executives, scientists entering industry, finance executives, and investors navigating the life sciences ecosystem, Dual Fluency delivers what no MBA curriculum and no conference panel ever could: the unvarnished logic of how science becomes strategy, and how strategy becomes value. "The most powerful life sciences leaders are those who can move fluidly between scientific truth and financial reality and build organizations that do the same. Leadership in this sector is not just about managing people. It is about managing translation: between data and capital, between discovery and deal, between boardroom and boardroom."
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
David H. Crean is the author of Dual Fluency. He is founder and managing partner of Cardiff Advisory, an investment banking M&A firm focused on healthcare and life sciences companies. His career has taken him from scientist to corporate and business development, M&A, investment banking, venture capital and entrepreneurship. Today he advises companies on issues of growth, partnering, and exit while also leading CEO360, a peer-to-peer platform for early stage life sciences companies.His career over 30 years has evolved because he kept learning, built relationships with people who could help him grow, became comfortable moving into unfamiliar territory and eventually began sharing what he learned with others. Those same ideas now show up throughout his work with Cardiff Advisory, CEO360 and Dual Fluency.
Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.
Vos droits au titre de la garantie légale : Chaque consommateur de l'UE bénéficie d'au moins deux ans de protection au titre de la garantie légale pour tout bien de consommation vendu dans l'UE. Voir plus
Vendeur : California Books, Miami, FL, Etats-Unis
Etat : New. N° de réf. du vendeur I-9798952851160
Quantité disponible : Plus de 20 disponibles
Vendeur : Grand Eagle Retail, Bensenville, IL, Etats-Unis
Hardcover. Etat : new. Hardcover. What separates the life sciences CEOs who build enduring companies from those who don't?In life sciences, the answer is rarely pedigree, network, or technical knowledge alone. It is the ability to speak two languages simultaneously, the language of science and the language of capital, and to be trusted in both rooms.Dual Fluency is the practitioner's guide to mastering that rare combination. Drawing on more than thirty years spanning M&A, licensing, partnering, and capital raises across numerous therapeutic disciplines, David H. Crean, PhD, MBA offers an unfiltered view of how transformative companies get built and sold and why so many promising ones quietly fall apart.This is not a textbook. It is not a retrospective written from the comfort of retirement. It is the operating thesis of a working professional who has sat on both sides of the table inside large pharma, alongside venture and private equity capital providers, and at the advisory helm of investment banking for some of the sector's most complex transactions.For founders, CEOs, business development executives, scientists entering industry, finance executives, and investors navigating the life sciences ecosystem, Dual Fluency delivers what no MBA curriculum and no conference panel ever could: the unvarnished logic of how science becomes strategy, and how strategy becomes value."The most powerful life sciences leaders are those who can move fluidly between scientific truth and financial reality and build organizations that do the same. Leadership in this sector is not just about managing people. It is about managing translation: between data and capital, between discovery and deal, between boardroom and boardroom." This item is printed on demand. Shipping may be from multiple locations in the US or from the UK, depending on stock availability. N° de réf. du vendeur 9798952851160
Quantité disponible : 1 disponible(s)
Vendeur : PBShop.store US, Wood Dale, IL, Etats-Unis
HRD. Etat : New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000. N° de réf. du vendeur L1-9798952851160
Quantité disponible : Plus de 20 disponibles
Vendeur : PBShop.store UK, Fairford, GLOS, Royaume-Uni
HRD. Etat : New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000. N° de réf. du vendeur L1-9798952851160
Quantité disponible : Plus de 20 disponibles
Vendeur : CitiRetail, Stevenage, Royaume-Uni
Hardcover. Etat : new. Hardcover. What separates the life sciences CEOs who build enduring companies from those who don't?In life sciences, the answer is rarely pedigree, network, or technical knowledge alone. It is the ability to speak two languages simultaneously, the language of science and the language of capital, and to be trusted in both rooms.Dual Fluency is the practitioner's guide to mastering that rare combination. Drawing on more than thirty years spanning M&A, licensing, partnering, and capital raises across numerous therapeutic disciplines, David H. Crean, PhD, MBA offers an unfiltered view of how transformative companies get built and sold and why so many promising ones quietly fall apart.This is not a textbook. It is not a retrospective written from the comfort of retirement. It is the operating thesis of a working professional who has sat on both sides of the table inside large pharma, alongside venture and private equity capital providers, and at the advisory helm of investment banking for some of the sector's most complex transactions.For founders, CEOs, business development executives, scientists entering industry, finance executives, and investors navigating the life sciences ecosystem, Dual Fluency delivers what no MBA curriculum and no conference panel ever could: the unvarnished logic of how science becomes strategy, and how strategy becomes value."The most powerful life sciences leaders are those who can move fluidly between scientific truth and financial reality and build organizations that do the same. Leadership in this sector is not just about managing people. It is about managing translation: between data and capital, between discovery and deal, between boardroom and boardroom." This item is printed on demand. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability. N° de réf. du vendeur 9798952851160
Quantité disponible : 1 disponible(s)
Vendeur : AussieBookSeller, Truganina, VIC, Australie
Hardcover. Etat : new. Hardcover. What separates the life sciences CEOs who build enduring companies from those who don't?In life sciences, the answer is rarely pedigree, network, or technical knowledge alone. It is the ability to speak two languages simultaneously, the language of science and the language of capital, and to be trusted in both rooms.Dual Fluency is the practitioner's guide to mastering that rare combination. Drawing on more than thirty years spanning M&A, licensing, partnering, and capital raises across numerous therapeutic disciplines, David H. Crean, PhD, MBA offers an unfiltered view of how transformative companies get built and sold and why so many promising ones quietly fall apart.This is not a textbook. It is not a retrospective written from the comfort of retirement. It is the operating thesis of a working professional who has sat on both sides of the table inside large pharma, alongside venture and private equity capital providers, and at the advisory helm of investment banking for some of the sector's most complex transactions.For founders, CEOs, business development executives, scientists entering industry, finance executives, and investors navigating the life sciences ecosystem, Dual Fluency delivers what no MBA curriculum and no conference panel ever could: the unvarnished logic of how science becomes strategy, and how strategy becomes value."The most powerful life sciences leaders are those who can move fluidly between scientific truth and financial reality and build organizations that do the same. Leadership in this sector is not just about managing people. It is about managing translation: between data and capital, between discovery and deal, between boardroom and boardroom." This item is printed on demand. Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability. N° de réf. du vendeur 9798952851160
Quantité disponible : 1 disponible(s)
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
Buch. Etat : Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - What separates the life sciences CEOs who build enduring companies from those who don't In life sciences, the answer is rarely pedigree, network, or technical knowledge alone. It is the ability to speak two languages simultaneously, the language of science and the language of capital, and to be trusted in both rooms.Dual Fluency is the practitioner's guide to mastering that rare combination. Drawing on more than thirty years spanning M&A, licensing, partnering, and capital raises across numerous therapeutic disciplines, David H. Crean, PhD, MBA offers an unfiltered view of how transformative companies get built and sold and why so many promising ones quietly fall apart.This is not a textbook. It is not a retrospective written from the comfort of retirement. It is the operating thesis of a working professional who has sat on both sides of the table inside large pharma, alongside venture and private equity capital providers, and at the advisory helm of investment banking for some of the sector's most complex transactions.For founders, CEOs, business development executives, scientists entering industry, finance executives, and investors navigating the life sciences ecosystem, Dual Fluency delivers what no MBA curriculum and no conference panel ever could: the unvarnished logic of how science becomes strategy, and how strategy becomes value.'The most powerful life sciences leaders are those who can move fluidly between scientific truth and financial reality and build organizations that do the same. Leadership in this sector is not just about managing people. It is about managing translation: between data and capital, between discovery and deal, between boardroom and boardroom.'. N° de réf. du vendeur 9798952851160
Quantité disponible : 2 disponible(s)
Vendeur : Home-set, Mannheim, Allemagne
Gebundene Ausgabe. Etat : Neu. What separates the life sciences CEOs who build enduring companies from those who don't?In life sciences, the answer is rarely pedigree, network, or technical knowledge alone. It is the ability to speak two languages simultaneously, the language of science and the language of capital, and to be trusted in both rooms.Dual Fluency is the practitioner's guide to mastering that rare combination. Drawing on more than thirty years spanning M&A, licensing, partnering, and capital raises across numerous therapeutic disciplines, David H. Crean, PhD, MBA offers an unfiltered view of how transformative companies get built and sold and why so many promising ones quietly fall apart.This is not a textbook. It is not a retrospective written from the comfort of retirement. It is the operating thesis of a working professional who has sat on both sides of the table inside large pharma, alongside venture and private equity capital providers, and at the advisory helm of investment banking for some of the sector's most complex transactions.For founders, CEOs, business development executives, scientists entering industry, finance executives, and investors navigating the life sciences ecosystem, Dual Fluency delivers what no MBA curriculum and no conference panel ever could: the unvarnished logic of how science becomes strategy, and how strategy becomes value."The most powerful life sciences leaders are those who can move fluidly between scientific truth and financial reality and build organizations that do the same. Leadership in this sector is not just about managing people. It is about managing translation: between data and capital, between discovery and deal, between boardroom and boardroom." Sprache: Englisch Gewicht in Gramm: 412. N° de réf. du vendeur IB-11502515
Quantité disponible : 2 disponible(s)
Vendeur : preigu, Osnabrück, Allemagne
Buch. Etat : Neu. Dual Fluency | The Language of Science and Capital in Life Sciences | David H. Crean | Buch | Englisch | 2026 | David H. Crean | EAN 9798952851160 | Verantwortliche Person für die EU: Libri GmbH, Europaallee 1, 36244 Bad Hersfeld, gpsr[at]libri[dot]de | Anbieter: preigu Print on Demand. N° de réf. du vendeur 136825490
Quantité disponible : 5 disponible(s)